The document is a landscape chart of psychedelic therapeutic companies and their development stages of various psychedelic compounds and therapies. It shows over 30 companies developing psychedelic-based therapies including psilocybin, ketamine, MDMA, and DMT in preclinical through phase 3 trials. The chart provides an overview of the lead agents, base compounds, and development phases of different companies in the emerging psychedelic medicine field.
The document is a landscape chart of psychedelic therapeutic companies and their development stages of various psychedelic compounds and therapies. It shows over 30 companies developing psychedelic-based therapies including psilocybin, ketamine, MDMA, and DMT in preclinical through phase 3 trials. The chart provides an overview of the lead agents, base compounds, and development phases of different companies in the emerging psychedelic medicine field.
The document is a landscape chart of psychedelic therapeutic companies and their development stages of various psychedelic compounds and therapies. It shows over 30 companies developing psychedelic-based therapies including psilocybin, ketamine, MDMA, and DMT in preclinical through phase 3 trials. The chart provides an overview of the lead agents, base compounds, and development phases of different companies in the emerging psychedelic medicine field.